<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04612894</url>
  </required_header>
  <id_info>
    <org_study_id>CALA-TC</org_study_id>
    <nct_id>NCT04612894</nct_id>
  </id_info>
  <brief_title>Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer</brief_title>
  <official_title>The Efficacy and Safety of Anti-PD-1 Antibody Camrelizumab Combined With Apatinib for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer: a Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy and safety of anti-PD-1 antibody Camrelizumab combined with&#xD;
      Apatinib for neoadjuvant therapy in locally advanced thyroid cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>ORR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0/1 resection rate</measure>
    <time_frame>at the time of surgery</time_frame>
    <description>R0/1 resection rate if operable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>at the time point of 6 weeks</time_frame>
    <description>DCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>from the first drug administration to within 90 days after surgery</time_frame>
    <description>AEs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant Camrelizumab + Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib 250mg, po qd, and Camrelizumab 200mg, iv q2w as neoadjuvant treatment. 28 days as one cycle, for at least two cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab and Apatinib</intervention_name>
    <description>All patients will receive Camrelizumab and Apatinib for at least two cycles of neoadjuvant treatment</description>
    <arm_group_label>Neoadjuvant Camrelizumab + Apatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
    <description>Perform surgery if operable after neoadjuvant therapy</description>
    <arm_group_label>Neoadjuvant Camrelizumab + Apatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>core needle biopsy</intervention_name>
    <description>Perform core needle biopsy if inoperable after neoadjuvant therapy</description>
    <arm_group_label>Neoadjuvant Camrelizumab + Apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient volunteered to participate in the study and signed an informed consent&#xD;
             form;&#xD;
&#xD;
          -  Pathologically diagnosed locally advanced thyroid cancer, including papillary thyroid&#xD;
             cancer, medullary cancer, follicular cancer, poorly differentiated cancer, etc.,&#xD;
             require surgical resection with or without distant metastasis;&#xD;
&#xD;
          -  Preoperative assessment of locally advanced thyroid cancer (unable to achieve R0/1&#xD;
             resection or T4 disease);&#xD;
&#xD;
          -  Have at least one measurable lesion (RECIST 1.1);&#xD;
&#xD;
          -  Age&gt;=14 years, Eastern Cooperative Oncology Group (ECOG) score 0-1;&#xD;
&#xD;
          -  Patient agree to receive surgery/ core needle biopsy before and after neoadjuvant&#xD;
             treatment.&#xD;
&#xD;
          -  The main organ functions meet the criteria before treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have previously been treated with immune checkpoint inhibitors (including&#xD;
             but not limited to nivolizumab, pembrolizumab, teriplizumab, sintilizumab, etc.);&#xD;
&#xD;
          -  Received external radiation therapy or iodine-131 therapy within the past 28 days; or&#xD;
             planned systemic anti-tumor therapy during this study;&#xD;
&#xD;
          -  Pathologically confirmed non-thyroid epithelial cell-derived malignant tumors&#xD;
             (including lymphoma, metastatic cancer, sarcoma, etc.);&#xD;
&#xD;
          -  With other uncontrolled / under treatment malignancies;&#xD;
&#xD;
          -  Those who have multiple factors (such as inability to swallow) that affect oral&#xD;
             medication;&#xD;
&#xD;
          -  Patients with any severe and / or uncontrolled illness,&#xD;
&#xD;
          -  Patients whose imaging showed that the tumor had invaded the important blood vessels&#xD;
             or the researchers judged that the tumor was likely to invade important blood vessels&#xD;
             during the subsequent study period and caused fatal bleeding;&#xD;
&#xD;
          -  According to the investigator's judgment, there are concomitant diseases that&#xD;
             seriously endanger the safety of patients or affect patients to complete the research.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yu Wang, M.D.</last_name>
    <phone>86-021-64175590</phone>
    <phone_ext>65805</phone_ext>
    <email>neck130@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nai-si Huang, M.D.</last_name>
    <phone>86-021-64175590</phone>
    <phone_ext>67816</phone_ext>
    <email>huangnaisi@fudan.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yu Wang, M.D.</last_name>
      <phone>86-021-64175590</phone>
      <phone_ext>65805</phone_ext>
      <email>neck130@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>thyroid cancer</keyword>
  <keyword>locally advanced</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>Camrelizumab</keyword>
  <keyword>Apatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

